Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 25,707,368 $ 4,515,398
Accounts receivable - project revenue and reimbursable project costs 10,400
Other receivable from joint venture 414,957
Prepaid expenses and other current assets 107,861 70,067
Deferred financing cost, net 491,168
Total Current Assets 26,230,186 5,087,033
Investment in joint venture 2,415,228
Other Assets    
Patent costs 1,506,672 1,367,692
Deferred financing cost, net 491,268
Total Other Assets 1,506,672 1,858,960
Total Assets 30,152,086 6,945,993
Current Liabilities    
Accounts payable and accrued liabilities 1,405,341 1,151,210
Total Current Liabilities 1,405,341 1,151,210
Total Liabilities 1,405,341 1,151,210
Commitments and Contingencies - Note 5
Stockholders' Equity    
Common stock, $0.001 par value, 100,000,000 authorized, 28,621,758 shares and 12,737,703 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively 28,622 12,738
Additional paid-in capital 124,774,561 93,602,539
Accumulated deficit (96,060,014) (87,821,514)
Total Stockholders' Equity 28,746,745 5,794,783
Total Liabilities and Stockholders' Equity 30,152,086 6,945,993
Convertible Series A Preferred Shares    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: 909 1,020
Convertible Series B Preferred Shares    
Stockholders' Equity    
Preferred stock, $0.001 par value, 10,000,000 authorized shares: $ 2,667